The effect of Defroxamine on Neurological and Radiological Outcome after Spontaneous Intracerebral Hemorrhage

Abstract

There is little clinical information about the role of deferoxamine in human studies. Considering that most of the studies conducted in this case were on animals and there are few clinical results in human studies that indicate that this drug is safe for humans and considering that no such study has been conducted in Iran so far. We decided to investigate the effect of Defroxamine on cerebral edema and improvement of neurological and radiological function in patients with spontaneous cerebral hemorrhages. Materials and Methods: The current study is a randomized and double-blind clinical trial that was conducted during the first six months of 2011 in Tabriz Faculty of Medical Sciences with the participation of 42 patients with spontaneous cerebral hemorrhage. Patients were randomly divided into two control and intervention groups. The control group received routine treatments, but the intervention group received deferoxamine in addition to routine treatments. According to previous studies, the dose of defroxamine is 7.5 mg/kg per hour, which was repeated for three consecutive days. Hematoma size, GCS score and mortality rate were compared between the two groups Results GCS changes in the intervention group were significantly higher than the control group until the fourth day; However, from the fourth day onwards, this average was not significant; The comparison of patients' GCS indicated that this criterion improved quickly in patients of the intervention group, while the onset of recovery was very slow in the patients of the control group. Comparing the volume of bleeding and cerebral edema on the third and seventh day indicated that the amount of bleeding in the intervention group was significantly lower than the control group on both days..